F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Post-Effective Amendment to Registration Statement
Oncolytics Biotech files post-effective amendment to deregister unsold securities from multiple prior registration statements.
Summary
- Oncolytics Biotech Inc. has filed a post-effective amendment to several of its Form F-10 registration statements.
- The primary purpose of this filing is to deregister securities that were registered but not sold under these previous statements.
- This action pertains to multiple registration statements filed between 2007 and 2024, covering various securities including units, common shares, subscription receipts, and warrants.
- The amendment specifically revises the designated effectiveness date and time for the registration statements to April 8, 2026, at 4:30 p.m. Eastern time.
- No other changes have been made to the registration statements as previously amended.
Sentiment
Score: 2
Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to its administrative nature and implication of past offerings not fully utilizing registered securities, though it's primarily a procedural cleanup.
Future Outlook
The filing does not contain forward-looking statements or guidance; it is solely an administrative amendment to deregister unsold securities.
Industry Context
StockSavvy.ai notes that this filing is a procedural step related to past capital-raising activities and does not reflect current operational performance or future strategic direction. Companies often deregister unsold securities to clean up their filings and reduce administrative burden.
Stakeholder Impact
- Shareholders: No direct impact on current share value or ownership, but it signifies the conclusion of certain past offering periods.
Next Steps
- The registration statements will become effective on April 8, 2026, at 4:30 p.m. Eastern time for the purpose of deregistering unsold securities.
Key Dates
| Date | Description |
|---|---|
| February 2, 2007 | Initial filing date for Registration Statement No. 333-140460. |
| February 8, 2007 | Initial filing date for Registration Statement No. 333-140529. |
| June 6, 2008 | Initial filing date for Registration Statement No. 333-151513. |
| June 2, 2010 | Initial filing date for Registration Statement No. 333-167250. |
| June 21, 2012 | Initial filing date for Registration Statement No. 333-182260. |
| July 25, 2014 | Initial filing date for Registration Statement No. 333-197633. |
| April 25, 2018 | Initial filing date for Registration Statement No. 333-224432. |
| June 8, 2020 | Initial filing date for Registration Statement No. 333-239025. |
| June 10, 2022 | Initial filing date for Registration Statement No. 333-265510. |
| July 25, 2024 | Initial filing date for Registration Statement No. 333-281009. |
| April 6, 2026 | Date of filing of Post-Effective Amendment No. 2. |
| April 8, 2026 | Designated effectiveness date and time for the registration statements. |
Keywords
Oncolytics Biotech, SEC Filing, Form F-10, Registration Statement, Deregistration, Securities, Amendment, Unsold Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.